Maigaard S, Frimodt-Möller N, Madsen P O
Antimicrob Agents Chemother. 1978 Oct;14(4):544-8. doi: 10.1128/AAC.14.4.544.
Netilmicin and amikacin, two recently developed aminoglycosides, were compared in a prospective, randomized study of 57 male patients with complicated urinary tract infections. Both drugs were administered intramuscularly every 12 h for 7 to 10 days, netilmicin at 2 mg/kg and amikacin at 7.5 mg/kg. The two groups were comparable as to infecting bacteria and underlying pathology of the urinary tract. No patients had indwelling catheters. All microorganisms isolated were sensitive to both antibiotics. A total of 69% of the patients treated with netilmicin and 57% of the patients treated with amikacin were cured of the infection, as defined by a negative culture at 7 days after discontinuation of treatment. No major side effects were recorded, and no significant changes were noted in parameters of renal function. Of the patients treated with amikacin, 21% experienced temporary local pain at the injection site; no such effect was noted in the netilmicin-treated group. Therefore, netilmicin appeared to be as effective and better tolerated than did amikacin in the treatment of complicated urinary tract infection.
在一项针对57例患有复杂性尿路感染的男性患者的前瞻性随机研究中,对新近开发的两种氨基糖苷类药物奈替米星和阿米卡星进行了比较。两种药物均每12小时肌肉注射一次,持续7至10天,奈替米星剂量为2mg/kg,阿米卡星剂量为7.5mg/kg。两组在感染细菌和尿路基础病理方面具有可比性。所有患者均未留置导尿管。分离出的所有微生物对两种抗生素均敏感。按照治疗停止7天后培养结果为阴性来定义,接受奈替米星治疗的患者中共有69%感染治愈,接受阿米卡星治疗的患者中这一比例为57%。未记录到严重副作用,肾功能参数也未发现显著变化。接受阿米卡星治疗的患者中,21%在注射部位出现了暂时性局部疼痛;奈替米星治疗组未观察到此类情况。因此,在治疗复杂性尿路感染方面,奈替米星似乎与阿米卡星疗效相当,但耐受性更好。